Cath developer Roxwood Medical said today it inked an exclusive distribution deal granting Abbott (NYSE:ABT) to distribute its products in the US.
Through the deal, Abbott will gain exclusive distribution rights to Roxwood’s anchoring catheters and microcatheters, including the CenterCross Ultra, MultiCross and MicroCross devices designed for the percutaneous treatment of chronic blockages.
“This partnership with Abbott’s vascular business is a major milestone for Roxwood that allows far more patients to benefit from our catheter portfolio used during complex coronary procedures. We have an amazing team at Roxwood, and are excited to work with Abbott to help patients suffering from advanced coronary artery disease,” Roxwood Medical CEO Mehrdad Farhangnia said in a press release.
Roxwood’s products will join Abbott’s devices, including its Xience drug eluting stent and Optis integrated optical coherence tomography system, the Redwood City, Calif.-based developer said.
“Our Xience stent is unparalleled when it comes to safety in complex PCI cases. The inclusion of Roxwood products in our industry-leading portfolio allows Abbott to provide a comprehensive solution for the most difficult cases, including chronic total occlusions,” Abbott US vascular sales, marketing & ops VP Jim Mayberry said in a prepared statement.
Earlier today, Abbott said it enrolled the 1st patient in a trial evaluating the short-term use of blood thinning drugs, called dual antiplatelet therapy, after implantation of the company’s Xience everolimus-eluting coronary stent.
